Channelopathies
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although aberrant expression of TREK-1 is implicated in cognitive impairment, the cellular and functional mechanism underlying this channelopathy is poorly understood.
|
31728930 |
2020 |
Brain Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
TWIK-related potassium channel-1 (TREK-1) is broadly expressed in the brain and involved in diverse brain diseases, such as seizures, ischemia, and depression.
|
31771312 |
2019 |
Lower Urinary Tract Symptoms
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The aim of this study was to compare single nucleotide polymorphisms (SNPs) in TREK-1 channel between patients with LUTS and healthy donors.
|
30350878 |
2019 |
MOHR-TRANEBJAERG SYNDROME
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, an appropriate length MTS (MethaneThioSulfonate) cross-linking reagent (MTS14) restricted the activation of TREK-1_A286C channels by repeated application of FFA.
|
31455781 |
2019 |
Post MI
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our data suggest that TREK-1 has a protective effect against I/R-induced injury and influences the post-MI remodeling processes by regulating membrane potential and maintaining intracellular Ca<sup>2+</sup> homeostasis.
|
31511966 |
2019 |
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, ROC curves indicated that KCNK2, KCNK9, KCNK15, and KCNK17 levels could be used as a diagnostic biomarker for HCC.
|
31581133 |
2019 |
Post stroke depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
This work reveals the first evidence that the modulation of TREK-1 channels in the early and chronic phases of stroke as well as the stimulation of brain plasticity by mini-spadin could play a key role in its brain protective effects against stroke and its deleterious consequences such as PSD.
|
31325429 |
2019 |
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
TREK-1 is multi-regulated by a variety of physical and chemical stimuli which makes it a very promising and challenging target in the treatment of several pathologies.
|
31031627 |
2019 |
Bladder neck obstruction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Increased Expression of TREK-1 K+ Channel in the Dorsal Root Ganglion of Rats with Detrusor Overactivity After Partial Bladder Outlet Obstruction.
|
29462125 |
2018 |
Neuralgia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Our findings suggested that miR-183-5P participated in the regulation of CCI-induced neuropathic pain through inhibiting the expression of TREK-1.
|
29736614 |
2018 |
Cardiac fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The absence of pressure overload-induced dysfunction in TREK-1-KO mice was associated with diminished cardiac fibrosis and reduced activation of JNK in cardiomyocytes and fibroblasts.
|
30153110 |
2018 |
Acute cerebral ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two-pore domain potassium channel TREK-1 was known to play an important role in neuroprotection, especially in acute cerebral ischemia.
|
29438799 |
2018 |
Atrial Fibrillation
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene transfer effectively increased TREK-1 protein levels and attenuated atrial effective refractory period prolongation in the porcine AF model.
|
28005193 |
2017 |
Tachycardia, Ventricular
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sodium permeable and "hypersensitive" TREK-1 channels cause ventricular tachycardia.
|
28242754 |
2017 |
Forgetful
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our data demonstrate that inhibition of TREK-1 protects mice from cognitive impairment induced by anesthesia and TREK-1 is a potential therapeutic target against memory impairment induced by volatile anesthetics.
|
29042297 |
2017 |
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
pH-sensitive K(+) channel TREK-1 is a novel target in pancreatic cancer.
|
27443495 |
2016 |
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
pH-sensitive K(+) channel TREK-1 is a novel target in pancreatic cancer.
|
27443495 |
2016 |
Spinal Cord Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recent literature suggests lactate to be neuroprotective and TREK1 knockout mice show an increased sensitivity to brain and spinal cord ischaemia; however, the connecting link between the two is missing.
|
26445100 |
2016 |
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
TREK-1 may therefore be a promising novel target for PDAC therapy.
|
27443495 |
2016 |
Allergic rhinitis (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Regulation of Trek1 expression in nasal mucosa with allergic rhinitis by specific immunotherapy.
|
25529528 |
2015 |
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate that TREK-M can silence hyperexcitable neurons in the brain of epileptic rats and treat acute seizures.
|
24299204 |
2014 |
Status Epilepticus
|
0.010 |
Biomarker
|
disease |
BEFREE |
To test if adenoassociated viral (AAV) delivery of TREK-M could reduce the duration of status epilepticus and reduce neuronal death induced by lithium-pilocarpine administration.
|
24299204 |
2014 |
Middle Cerebral Artery Occlusion
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Rats that were preconditioned with sevoflurane were subjected to middle cerebral artery occlusion (MCAO), and the expression of TREK-1 protein and mRNA was analysed.
|
24154701 |
2014 |
Amyotrophic Lateral Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The severity of EAE was attenuated in mice given the amyotrophic lateral sclerosis drug riluzole or fed a diet enriched with linseed oil (which contains the TREK-1 activating omega-3 fatty acid α-linolenic acid).
|
23933981 |
2013 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The K2P channel blockers methanandamide, lidocaine, zinc and curcumin had antiproliferative effects (P < 0.01) in an endometrial epithelial cancer cell line indicating a role for TASK and TREK-1 channels in proliferation.
|
23305490 |
2013 |